Almotriptan

Summary

Almotriptan (CHEMBL1505) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC N02CC05) targeting HTR1B and HTR1D; indicated across 1 condition including migraine disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N02CC05
• Targets: 2 (HTR1B, HTR1D)
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 335.5 Da · C17H25N3O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1505
Name	Almotriptan
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	123606
ChEBI	CHEBI:520985
ATC	N02CC05
Molecular formula	C17H25N3O2S
Molecular weight	335.5
InChIKey	WKEMJKQOLOHJLZ-UHFFFAOYSA-N

SMILES: CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3

IUPAC name: N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine

ChEBI definition: An indole compound having a 2-(dimethylamino)ethyl group at the 3-position and a (pyrrolidin-1-ylsulfonyl)methyl group at the 5-position.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, serotonergic agonist, vasoconstrictor agent.

Also known as: Almotriptan, LAS 31416, LAS-31416, LAS31416, NSC-760092, SID26748976, almotriptan, ALMOTRIPTAN, SID174006290, SID170465288, Almotriptan malate (Axert)

Parent form; salt/anhydrous children: CHEMBL1200521

Patent coverage: 1,841 distinct patent families (7,443 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 7,418 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HTR1B	5-HT1B receptor	Agonist	7.92	0.2%	P28222
HTR1D	5-HT1D receptor	Agonist	7.89	0%	P28221

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Prelamin-A/C, 5-hydroxytryptamine receptor 2B, Alpha-2B adrenergic receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR2B	6.29	AC50	510	nM	CHEMBL_ACT_25163972
LMNA	5.35	Potency	4467	nM	CHEMBL_ACT_3641554

Target pathways

Aggregated over 2 target gene(s): HTR1B, HTR1D.

Top Reactome pathways

8 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	2	HTR1B, HTR1D
Signaling by GPCR	2	HTR1B, HTR1D
Class A/1 (Rhodopsin-like receptors)	2	HTR1B, HTR1D
Amine ligand-binding receptors	2	HTR1B, HTR1D
GPCR downstream signalling	2	HTR1B, HTR1D
Serotonin receptors	2	HTR1B, HTR1D
G alpha (i) signalling events	2	HTR1B, HTR1D
GPCR ligand binding	2	HTR1B, HTR1D

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	2
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	2
adenylate cyclase-inhibiting serotonin receptor signaling pathway	2
chemical synaptic transmission	2
vasoconstriction	2
regulation of behavior	2
signal transduction	2
G protein-coupled receptor signaling pathway	2
phospholipase C-activating serotonin receptor signaling pathway	1
negative regulation of serotonin secretion	1
bone remodeling	1
cellular response to alkaloid	1
cellular response to xenobiotic stimulus	1
positive regulation of vascular associated smooth muscle cell proliferation	1
intestine smooth muscle contraction	1

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
migraine disorder	2	MONDO:0005277	MONDO:0005277

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00432549	PHASE4	UNKNOWN	Detoxification and Treatment of Subjects With Medication Overuse Headache

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 7 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

51 molecules share ≥1 primary target. Top 51 by shared-target count:

Molecule	Source	Status	Shared targets
Dihydroergotamine	ChEMBL + PubChem	Phase 4 (approved)	HTR1B, HTR1D
PALIPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	HTR1B, HTR1D
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
AZELASTINE	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
CARIPRAZINE	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
ERGOTAMINE	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
FROVATRIPTAN	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
IMIPRAMINE	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
KETANSERIN	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
NARATRIPTAN	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
NEFAZODONE	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
OXYMETAZOLINE	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
RISPERIDONE	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
RIZATRIPTAN	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
SALMETEROL	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
SILODOSIN	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
SUMATRIPTAN	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
VILAZODONE	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
XYLOMETAZOLINE	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
ZOLMITRIPTAN	ChEMBL	Phase 4 (approved)	HTR1B, HTR1D
SEROTONIN	ChEMBL	Phase 3	HTR1B, HTR1D
YOHIMBINE	ChEMBL	Phase 3	HTR1B, HTR1D
ACETRYPTINE	ChEMBL	Phase 2	HTR1B, HTR1D
GSK163090	ChEMBL	Phase 2	HTR1B, HTR1D
MEBUFOTENIN	ChEMBL	Phase 2	HTR1B, HTR1D
PSILOCIN	ChEMBL	Phase 2	HTR1B, HTR1D
LASMIDITAN	ChEMBL + PubChem	Phase 4 (approved)	HTR1D
CINACALCET	ChEMBL	Phase 4 (approved)	HTR1D
CLOZAPINE	ChEMBL	Phase 4 (approved)	HTR1B
ELETRIPTAN	ChEMBL	Phase 4 (approved)	HTR1B
KETOTIFEN	ChEMBL	Phase 4 (approved)	HTR1B
LOPERAMIDE	ChEMBL	Phase 4 (approved)	HTR1D
MIANSERIN	ChEMBL	Phase 4 (approved)	HTR1D
OLANZAPINE	ChEMBL	Phase 4 (approved)	HTR1B
PINDOLOL	ChEMBL	Phase 4 (approved)	HTR1B
PRAMIPEXOLE	ChEMBL	Phase 4 (approved)	HTR1B
PRAZOSIN	ChEMBL	Phase 4 (approved)	HTR1D
SERTINDOLE	ChEMBL	Phase 4 (approved)	HTR1B
TEGASEROD	ChEMBL	Phase 4 (approved)	HTR1D
LATREPIRDINE	ChEMBL	Phase 3	HTR1D
ALNIDITAN	ChEMBL	Phase 2	HTR1D
ATUMELNANT	ChEMBL	Phase 2	HTR1B
LEVOPROPRANOLOL	ChEMBL	Phase 2	HTR1B
LYSERGIDE	ChEMBL	Phase 2	HTR1D
MAZAPERTINE	ChEMBL	Phase 2	HTR1B
NIGULDIPINE	ChEMBL	Phase 2	HTR1B
PENFLURIDOL	ChEMBL	Phase 2	HTR1D
PRUVANSERIN	ChEMBL	Phase 2	HTR1D
RITANSERIN	ChEMBL	Phase 2	HTR1B
SPIRAMIDE	ChEMBL	Phase 2	HTR1D